A randomized double-blind placebo-controlled multicenter trial assessing the impact of lipoprotein(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease

Brief description of study

The purpose of the study is to evaluate if the investigational treatment (pelacarsen) will be able to reduce the risk of cardiovascular (CV) disease in patients with elevated lipoprotein(a) (commonly called Lp(a)) when compared to placebo. Just like other particles in your blood, such as the ‘bad cholesterol’ known as LDL, lipoprotein(a) levels were found to be associated with the risk of hardening of the arteries, known as atherosclerosis. This can lead to conditions such as heart attacks, stroke or peripheral artery disease (severe pain in legs while walking or lower limb amputation). Pelacarsen (TQJ230) is a medicine that has not been approved by the FDA for the treatment of people with elevated lipoprotein(a).


Clinical Study Identifier: s20-01624
ClinicalTrials.gov Identifier: NCT04023552
Principal Investigator: Howard Weintraub.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.